Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nipocalimab in adults with generalized myasthenia gravis
CTR20212693Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Started Jun 2022; status: active.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20212693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212693.